Seclidemstat mesylate is under clinical development by Salarius Pharmaceuticals and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Seclidemstat mesylate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Seclidemstat mesylate overview
Seclidemstat (SP-2577) is under development for the treatment of relapsed and refractory Ewing’s sarcoma, prostate cancer, triple-negative breast cancer (TNBC), ovarian cancers including small cell carcinoma of the ovary hypercalcemic type (SCCOHT) and ovarian clear cell carcinoma (OCCC), pancreatic cancer, cervical cancer, endometrioid endometrial carcinoma (EEC), melanoma, colorectal cancer, myelodysplastic syndromes, chronic myelomonocytic leukemia, non-Ewing’s sarcomas, glioblastoma, hematological cancers, acute myelocytic leukemia (AML) (hematologic cancer), small cell lung cancer and other solid tumors. It is a small molecule which is administered through oral route in the form of tablet. The drug candidate acts by targeting lysine-specific histone demethylase 1 (LSD-1). The drug candidate was also under development for the treatment of non-small cell lung cancer, and myxoid liposarcoma, FET-rearranged sarcomas.
Salarius Pharmaceuticals overview
Salarius Pharmaceuticals, formerly Flex Pharma, is a biotechnology company. It develops drugs for pediatric and other cancers. It is investigating its lead compound Seclidemstat for the treatment of Ewing sarcoma, myxoid liposarcoma, FET-rearranged sarcomas, hematologic and gynecological cancers. The company is also evaluating SP-3164 and NCE 2nd generation LSD1i (lysine specific demethylase 1) programs against hematological and solid tumors. Salarius Pharmaceuticals is headquartered in Houston, Texas, the US.
For a complete picture of Seclidemstat mesylate’s drug-specific PTSR and LoA scores, buy the report here.